Earth Science Tech Inc. (OTC: ETST) is executing a dual strategy of expanding its healthcare platform while aggressively reducing its share count through repurchases, a move that may appeal to investors concerned about dilution in small-cap stocks. The company, which has evolved into a diversified healthcare holding company with operations spanning telemedicine, compounding pharmacies, clinical support services and healthcare fulfillment, has actively bought back shares as documented in SEC filings and share structure records.
According to the company’s most recent Form 10-Q, covering the quarter ended December 31, 2025, Earth Science Tech repurchased 1,143,000 common shares during that period for approximately $647,000. Over the nine months ended December 31, 2025, the company repurchased a total of 3.7 million shares. These repurchases reduce the number of outstanding shares, potentially increasing earnings per share and demonstrating management’s commitment to shareholder value.
For many investors evaluating companies on the OTC market, share structure often receives as much attention as revenue growth or acquisition activity. Earth Science Tech’s sustained repurchase program distinguishes it in terms of financial stability and capital allocation. The company continues to emphasize shareholder value through balance-sheet management alongside acquisitions and operating growth.
In addition to its repurchase activity, Earth Science Tech is scheduled to present to investors at the Planet MicroCap Las Vegas 2026 conference in June, providing an opportunity to showcase its evolving business model. The company’s platform spans multiple healthcare verticals, positioning it to capture growth in the expanding healthcare services sector.
The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST. For more details on the share repurchases, the Form 10-Q filing can be accessed at https://ibn.fm/Gm12j.
Earth Science Tech’s strategy of pairing operational expansion with share repurchases reflects a balanced approach to value creation. As the company continues to build its healthcare portfolio, the reduction in share count may provide a tailwind for shareholders, making it a noteworthy development in the small-cap healthcare space.
